Cargando…

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC

Mutual interactions between cancer cells and the tumor microenvironment importantly contribute to the development of tyrosine kinase inhibitor (TKI) resistance in patients affected by EGFR-mutant NSCLC. In particular, immune recognition-associated proteins with impact on tumor cell clearance through...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nigro, Annunziata, Ricciardi, Luca, Salvato, Ilaria, Sabbatino, Francesco, Vitale, Monica, Crescenzi, Maria Assunta, Montico, Barbara, Triggiani, Massimo, Pepe, Stefano, Stellato, Cristiana, Casolaro, Vincenzo, Dal Col, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004973/ https://www.ncbi.nlm.nih.gov/pubmed/32082304 http://dx.doi.org/10.3389/fimmu.2019.03135

Ejemplares similares

Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development
por: Montico, Barbara, et al.
Publicado: (2018)

Posttranscriptional Gene Regulatory Networks in Chronic Airway Inflammatory Diseases: In silico Mapping of RNA-Binding Protein Expression in Airway Epithelium
por: Ricciardi, Luca, et al.
Publicado: (2020)

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Phospholipid scramblase 1: a protein with multiple functions via multiple molecular interactors
por: Dal Col, Jessica, et al.
Publicado: (2022)

Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death
por: Lamberti, María Julia, et al.
Publicado: (2022)

Expression of targets of the RNA-binding protein AUF-1 in human airway epithelium indicates its role in cellular senescence and inflammation
por: Salvato, Ilaria, et al.
Publicado: (2023)

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome
por: Lamberti, María Julia, et al.
Publicado: (2021)

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
por: Lamberti, María Julia, et al.
Publicado: (2020)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Basic and clinical immunology – 3010. The RNA-binding protein HuR coordinately regulates GATA-3 and Th2 cytokine gene expression in dose dependent manner
por: Atasoy, Ulus, et al.
Publicado: (2013)

Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients
por: Ricciardi, Luca, et al.
Publicado: (2018)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
por: Liao, Tingting, et al.
Publicado: (2022)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
por: Dai, Lili, et al.
Publicado: (2022)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model
por: Tan, Jianlong, et al.
Publicado: (2017)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023)

Food Allergy and Intolerance: A Narrative Review on Nutritional Concerns
por: Gargano, Domenico, et al.
Publicado: (2021)

Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to cells
por: Tamarit, Lorena, et al.
Publicado: (2021)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
por: Cappuzzo, F, et al.
Publicado: (2004)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases
por: Cai, Linbo, et al.
Publicado: (2016)

A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
por: Lu, Xiaoxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4g5418kdb7ap5mie06ftdp5g7p